Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Total Liabilities (2021 - 2025)

Historic Total Liabilities for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $225.1 million.

  • ARS Pharmaceuticals' Total Liabilities rose 125443.66% to $225.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.1 million, marking a year-over-year increase of 125443.66%. This contributed to the annual value of $94.4 million for FY2024, which is 378612.03% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Total Liabilities stood at $225.1 million, which was up 125443.66% from $121.2 million recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Total Liabilities peaked at $225.1 million during Q3 2025, and registered a low of $2.4 million during Q4 2023.
  • Moreover, its 5-year median value for Total Liabilities was $15.2 million (2022), whereas its average is $37.6 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first crashed by 8046.7% in 2022, then surged by 378612.03% in 2024.
  • Over the past 5 years, ARS Pharmaceuticals' Total Liabilities (Quarter) stood at $16.7 million in 2021, then tumbled by 48.73% to $8.5 million in 2022, then tumbled by 71.6% to $2.4 million in 2023, then surged by 3786.12% to $94.4 million in 2024, then soared by 138.62% to $225.1 million in 2025.
  • Its Total Liabilities stands at $225.1 million for Q3 2025, versus $121.2 million for Q2 2025 and $98.3 million for Q1 2025.